Pharmafile Logo

KEYNOTE-177

- PMLiVE

No price ceiling for rare disease drugs, say MPs

BIA survey comes ahead of consultation on evaluation framework for ultra-orphans

- PMLiVE

AZ launches combination diabetes drug in UK

Xigduo combines Forxiga and metformin

NICE and ‘ultra orphans’

NICE and its processes for ‘highly specialised therapies’

- PMLiVE

NICE relents and backs Pfizer’s Inlyta

Recommends drug to treat advanced kidney cancer on NHS in England

National Institute for Health and Care Excellence NICE logo

NICE: Alexion must justify Soliris’ high cost

UK body unable to recommend ‘ultra-orphan’ drug

- PMLiVE

NICE set to reject Lilly’s Alimta for new use in lung cancer

Drug deemed not cost-effective use of NHS resources in new indication

- PMLiVE

NICE relents and gives Pixuvri limited backing

Recommends Cell Therapeutics drug for an aggressive form of cancer

- PMLiVE

NICE backs new use for Bayer’s Eylea

Will go up against Novartis’ Lucentis in treatment of macular oedema in UK

National Institute for Health and Care Excellence NICE logo

Janssen launches diabetes drug Invokana in UK

Launch coincides with draft NICE recommendation for the SGLT2 inhibitor

Biogen Idec building

NICE turns down Biogen Idec’s oral MS drug

UK HTA body says Tecfidera is not a cost-effective use of NHS resources

National Institute for Health and Care Excellence NICE logo

NICE calls for greater statin prescribing in wake of Lipitor generics

Wants more use of the drugs to help prevent cardiovascular disease

National Institute for Health and Care Excellence NICE logo

NICE reviews lung cancer drug guidance

Consults on availability of Roche's Tarceva and AZ's Iressa on NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links